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Abstract: Transforming growth factor beta (TGF-β) proteins are multifunctional cytokines 
whose neural functions are increasingly recognized. The machinery of TGF-β signaling, 
including the serine kinase type transmembrane receptors, is present in the central nervous 
system. However, the 3 mammalian TGF-β subtypes have distinct distributions in the brain 
suggesting different neural functions. Evidence of their involvement in the development 
and plasticity of the nervous system as well as their functions in peripheral organs 
suggested that they also exhibit neuroprotective functions. Indeed, TGF-β expression is 
induced following a variety of types of brain tissue injury. The neuroprotective function of 
TGF-βs is most established following brain ischemia. Damage in experimental animal 
models of global and focal ischemia was shown to be attenuated by TGF-βs. In addition, 
support for their neuroprotective actions following trauma, sclerosis multiplex, 
neurodegenerative diseases, infections, and brain tumors is also accumulating. The review 
will also describe the potential mechanisms of neuroprotection exerted by TGF-βs including 
anti-inflammatory, -apoptotic, -excitotoxic actions as well as the promotion of scar 
formation, angiogenesis, and neuroregeneration. The participation of these mechanisms in 
the neuroprotective effects of TGF-βs during different brain lesions will also be discussed. 
OPEN ACCESS
Int. J. Mol. Sci. 2012, 13 8220 
 
 
Keywords: TGF-β; stroke; lesion; brain injury; neurodegeneration; neuroprotection 
 
1. Introduction 
Transforming growth factors were originally named based on their abilities to induce a transformed 
phenotype in non-neoplastic rat kidney fibroblasts [1]. Transforming growth factor betas (TGF-βs) 
belong to a group of proteins that also includes bone morphogenic factors, anti-Mullerian hormone, 
activins and inhibins [2]. These proteins share some structural homology but possess separate receptors 
and participate in different functions. TGF-βs are prominent members of this group of proteins 
commonly referred to as the transforming growth factor beta superfamily. TGF-βs have pleiotropic 
functions in various organs. They regulate the growth, differentiation and survival of different cell 
types [3]. Therefore, they can be considered growth factors. They also influence different cells in the 
immune system, and consequently, are also considered cytokines [4]. TGF-βs include three 
mammalian isoforms (TGF-β1, -β2, and -β3). An additional three isoforms have been identified in 
lower vertebrate species [5]. TGF-β subtypes are encoded by separate genes but demonstrate sequence 
homology and have similar mechanisms for processing and activation [6]. 
TGF-βs are produced as pro-TGF-βs, which form dimers. Both proteins are cleaved in the Golgi 
apparatus and remain non-covalently associated in the so-called small latency associated complex of 
TGF-βs. The complex is covalently bound to latent TGF-β binding proteins (LTBPs) in the 
extracellular space and forms the large latent complex of TGF-β [7]. There are 4 LTBPs identified, 
however, only limited information is available on their selectivity to bind TGF-βs. In vitro, LTBP-1 
and LTBP-4 bind all three types of TGF-βs, LTBP-3 has some selectivity for TGF-β1 while LTBP-2 
does not seem to bind any TGF-βs [8]. 
The activation of TGF-βs requires their release from the large latent complex (Figure 1). There are 
several ways to induce the release TGF-βs in vitro including acidosis and proteolytic cleavage [9]. 
However, the exact physiological mechanisms remain to be determined. The free TGF-βs can travel as 
dimers to receptors at the extracellular surface of the target cell, and bind to heteromeric complexes of 
type I and II receptors, which belong to the serine/threonine kinase family of receptors. In most cells, 
TGF-βs signal via the canonical type I receptor TGF-β receptor I/activins-like kinase receptor 5 
(Alk5). In endothelial cells and in neurons, TGF-βs may also signal via the type I receptor Alk1 [10]. 
The type II receptor then phosphorylates the type I receptor, which relays the signal by binding and 
phosphorylating a receptor-regulated Smad protein [11]. Alk5 induces phosphorylation of Smads 2 and 
3 while Alk1 mediates phosphorylation of Smads 1, 5 and 8 [10]. The activated receptor-regulated 
Smad proteins form complexes with Smad4 [12]. Active Smad complexes translocate into the nucleus 
to exert their actions on gene expression [13]. TGF-βs may also use non-Smad signaling pathways 
including the phosphoinositide 3-kinase-Akt-mTOR pathway, the small GTPases Rho, Rac, and 
Cdc42, and the Ras-Erk-MAPK pathway [14]. 
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Figure 1. Summary diagram on the chemistry and actions of transforming growth factor 
beta (TGF-β)s in the nervous system. 
 
2. TGF-β in the Intact Brain 
2.1. The Distribution of TGF-βs, Their Binding Proteins and Receptors in the Brain 
The distribution pattern of TGF-βs was established at the protein level by means of 
immunohistochemistry [15] and at the mRNA level using in situ hybridization histochemistry [16] as 
summarized in Table 1. TGF-β1 immunoreactivity was reported to be constitutively present only in 
meninges and the choroid plexus in the brain [15,17] while a more widespread expression of the 
mRNA of this subtype was described including intense labeling in some cortical and hippocampal 
cells, the medial preoptic area, the paraventricular hypothalamic nucleus, the central amygdaloid 
nucleus, and the superior olive [16]. TGF-β2 and -β3 immunoreactivities were present in distinct layers 
of the cerebral cortex. In addition, some hippocampal regions, as well as widely distributed cells in the 
hypothalamus and amygdala contained TGF-β2 and -β3. Intense labeling of these subtypes was also 
described in brainstem monoaminergic neurons and motor nuclei [15,16]. In turn, the striatum, most 
thalamic nuclei, and the superior colliculus were almost devoid of TGF-β2 and -β3 mRNA and 
immunoreactivities. However, considerable differences between the distribution of mRNAs and 
immunoreactivities of TGF-βs have also been reported. TGF-β2 and -β3 immunoreactivities entirely 
overlapped and, in general, were found in large multipolar neurons [15] with the level of TGF-β2 
being considerably higher [18]. In some areas, including brainstem motoneurons and the area 
postrema, the 2 subtypes had similar mRNA expression patterns with high intensity labeling 
suggesting that different subtypes of TGF-βs may be co-expressed in the same cell. In most brain 
areas, however, the distributions of TGF-β2 and -β3 mRNAs were markedly different. In the cerebral 
cortex, TGF-βs were expressed in different layers. In the hippocampus, TGF-β2 was abundantly 
expressed only in the dentate gyrus while TGF-β3 in the CA2 region and the dentate gyrus. In the 
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cerebellum, TGF-β2 was present in the Purkinje cell layer while TGF-β3 mRNA was absent in the 
cerebellum. In addition, the medial mamillary nucleus, the parafascicular thalamic nucleus and the 
choroid plexus expressed predominantly TGF-β2 while the reticular thalamic nucleus, the superior 
colliculus, and the inferior olive contained almost exclusively TGF-β3 mRNA [16]. 
Table 1. Brain areas with high expression level of TGF-βs. 
Type of TGF-β Brain Regions 
TGF-β1 hippocampus; amygdala, central nucleus; hypothalamus, preoptic and paraventricular 
nuclei; midbrain; pons and medulla oblongata, reticular formation, motor nuclei, 
superior olive, area postrema; choroid plexus 
TGF-β2 cerebral cortex, layer V; dentate gyrus; thalamus, parafascicular and midline nuclei; 
hypothalamus, posterior part and mamillary body; midbrain, raphe nuclei; pons and 
medulla oblongata, reticular formation, motor nuclei, superior olive, area postrema; 
cerebellar cortex, Purkinje cell layer; choroid plexus 
TGF-β3 cerebral cortex, layers IV,VI; dentate gyrus; amygdala, basal nucleus; thalamus, 
anterior, ventral, midline and reticular nuclei; hypothalamus, arcuate and 
supramamillary nuclei; midbrain, superior colliculus; pons and medulla oblongata, 
reticular formation, motor nuclei, superior and inferior olive, area postrema 
The four subtypes of LTBPs also had distinct distribution patterns in the brain based on the 
localization of their mRNAs [19]. Comparison of the distribution of TGF-β and LTBP subtypes 
suggested that all three subtypes of TGF-βs are co-expressed with LTBP3 in the brain. In addition, 
TGF-βs might also bind to other types of LTBPs in certain brain regions. For example, the distribution 
of TGF-β1 and LTBP4 is similar in the supraoptic nucleus and the central nucleus of the amygdala. 
The choroid plexus, where TGF-β2 expression is dominant contains LTBP1 and 3. The inferior olive 
and the arcuate nucleus, brain areas with dominant TGF-β3 expression contain large amount of LTBP4 
and LTBP1, respectively [19]. Nevertheless, further double labeling studies are needed to actually 
establish co-expression of different subtypes of TGF-βs and LTBPs in single cells of the nervous 
system [20]. 
Although the topographical distribution of TGF-β receptors in the central nervous system (CNS) 
has not been systematically described, the available data suggest widespread localization. When  
TGF-β receptor mRNA was detected by RT-PCR in rats at different stages of development similar 
levels were found in several regions of the CNS, including cortex, midbrain, cerebellum, brain stem 
and hippocampus [21]. 
2.2. The Physiological Functions of TGF-βs in the Brain 
The physiological roles of TGF-βs in the nervous system are not fully understood. Their diverse 
roles in the development of the CNS have been established. Additional functions in neuronal 
transmission and neuroendocrine regulations have also been suggested recently (Figure 1). 
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2.2.1. The Role of TGF-βs in Brain Development 
During the development of the CNS, TGF-β immunolabeling was most prominent in zones where 
neuronal differentiation occurs and less intense in zones of active proliferation [22]. Subsequent in vitro 
experiments using quail neural crest cell demonstrated that TGF-β inhibited proliferation of neural 
crest cells while neurogenesis increased significantly in the presence of TGF-β [23,24]. TGF-β had an 
anti-mitotic effect on progenitors and increased expression of neuronal markers in hippocampal and 
cortical primary cell cultures of developing mouse [25]. These effects were dependent upon Smad4. 
TGF-β may also play a role in the regulation of adult neurogenesis as it had a pro-neurogenic effect in 
the dentate gyrus in a model of increased neurogenesis by adrenalectomy as well as in the 
subventricular zone when administered chronically with adenoviral vectors expressing TGF-β [26]. 
Furthermore, adrenalectomy increased TGF-β levels in the dentate gyrus while blockade of TGF-β 
biological activity by administration of an anti-TGF-β type II receptor antibody diminished 
neurogenesis [27]. Apart from playing a role in the adoption of neuronal cell fate, TGF-β may also be 
involved in the differentiation of selected neuronal subtypes at the expense of other subtypes. Within 
the intermediate and ventral domains, Smad3 promoted differentiation of ventral interneurons at the 
expense of motoneuron generation [28]. In turn, the survival of motoneurons may also depend on  
TGF-βs as a potentially continuous trophic support factor from muscle fibers or other cell types. Using 
cultures of purified chick embryonic motoneurons, TGF-βs acted synergistically with basic fibroblast 
growth factor to keep motoneurons alive [29]. Indeed, motoneurons were shown to synthesize TGF-β 
receptors and to transport them anterogradely, where they were inserted into the axonal membrane and 
nerve terminal [30]. Furthermore, TGF-β2 was detected in the synaptic portions of muscle fibers, 
motoneurons and in injured nerves, indicating that motoneurons may be exposed to multiple and 
potentially redundant sources of TGF-β2 [30]. In addition, double-ligation experiments were used to 
demonstrate that motoneurons transport TGF-β2 up and down their axons [30]. To test the effect of 
TGF-β on motoneuron survival in vivo, TGF-β2 was administered to the hypoglossal nucleus 
following the avulsion of the hypoglossal nerve in adult rats, which caused a significant attenuation of 
the motoneuron cell death [31]. TGF-β2 was, however, unable to prevent or reduce the  
axotomy-induced down regulation of choline acetyltransferase suggesting that TGF-β2 is only one of 
the growth factors regulating the homeostasis of motoneurons [31]. A role of TGF-β in the 
differentiation and survival of other, as yet unexplored neuronal cell types might also be possible.  
As far as glial cells, data are available that TGF-β regulates Schwann cell proliferation induced by 
neuronal contact in the peripheral nervous system [32,33]. 
The effect of TGF-β on synaptogenesis has also been proposed. In particular, TGF-β1 was identified 
as the molecule responsible for the synaptogenesis promoting effect of Schwann cell-conditioned 
medium in Xenopus nerve-muscle co-cultures [34]. TGF-β1 increased agrin expression and 
synaptogenesis along nerve-muscle contacts while immunodepletion of TGF-β1 with a specific 
antibody abolished the synaptogenic effect of Schwann cell-conditioned medium [34]. These results 
indicate that TGF-β1 may be a glial signal that instructs neurons to switch from a “growth state” to a 
“synaptogenic state”. 
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2.2.2. TGF-βs and the Modulation of Synaptic Transmission 
TGF-β2 was demonstrated to influence synaptic transmission, rather than synaptogenesis, at some 
central synapses [35]. TGF-β2 was found to be essential for proper synaptic function in the  
pre-Botzinger complex, a central rhythm organizer located in the brainstem while it was not crucial for 
the morphology and function of the neuromuscular junction of the diaphragm muscle. Genetic deletion 
of TGF-β2 in mice strongly impaired both GABA/glycinergic and glutamatergic synaptic transmission 
in the pre-Botzinger complex area, while numbers and morphology of central synapses of knock-out 
animals were indistinguishable from their wild-type littermates [35]. The role of TGF-β in synaptic 
transmission might be the basis of its proposed function in synaptic facilitation. Prolonged treatment 
with TGF-β2 induced facilitation of evoked postsynaptic currents in hippocampal neurons suggesting 
that it may play a role in the cascade of events underlying long-term synaptic facilitation [36].  
2.2.3. Proposed Neuroendocrine Functions of TGF-βs 
The potential involvement of TGF-β in central reproductive regulation is also an emerging topic. 
Gonadotropin-releasing hormone (GnRH) neurons in the preoptic area contain TGF-β receptors as well 
as SMAD2/3 suggesting that they are fully capable of responding directly to TGF-β1 stimulation [37]. 
Subsequent double-labeling experiments showed that astrocytes in the preoptic area expressed TGF-β1 
mRNA and that GnRH perikarya were often found in close association with TGF-β1 mRNA-expressing 
cells [38]. TGF-β1 was shown to be a neuroprotective component of astrocyte-induced medium 
[39,40] suggesting the ability of astrocytes to release TGF-βs. Furthermore, incubation of preoptic 
explants with TGF-β1 caused a significant, dose-dependent decrease in GnRH mRNA expression in 
individual neurons. This effect was inhibited by addition of the soluble form of TGF-β receptor II to 
the incubation medium [38]. These results support that astrocyte-derived TGF-β1 may directly 
influence GnRH expression and/or secretion in vivo by acting on the perikarya of GnRH neurons [20].  
TGF-β1 and -β3 also co-localize with arginine vasopressin in magnocellular neurons of the 
supraoptic and paraventricular nuclei of the hypothalamus suggesting that TGF-β secreted by the 
neurohypophysis might regulate the proliferation and secretion of certain anterior pituitary cells [41]. 
Furthermore, a diurnal pattern of expression of TGF-β as well as SMAD3 was found in the 
suprachiasmatic and paraventricular nuclei of young animals, a rhythm that was not observed in older 
mice suggesting a diurnal and age-dependent function of the TGF-β system in these nuclei [42]. So far, 
the regulatory role of TGF-β on hormone secretion, gene transcription, and cellular growth of 
prolactin-producing cells has been shown. TGF-β inhibited the transcriptional activity of the estrogen 
receptor although estrogens had no effect on TGF-β specific Smad protein transcriptional activity in 
prolactin producing cells [43]. Interactions of TGF-β and estrogen have been demonstrated for brain 
cells as well. A neuroprotective action of estrogen was suggested to be mediated by TGF-β released 
from astrocytes [40].  
These initial studies support the involvement of TGF-βs in a variety of neuroendocrine regulations. 
TGF-βs may interact with established neuropeptides reducing the conceptual gap between growth 
factors/cytokines and regulatory neuropeptides. The newly proposed neuroendocrine actions are also 
consistent with the widespread expression of TGF-βs in various hypothalamic centers even in the adult 
Int. J. Mol. Sci. 2012, 13 8225 
 
 
animals. Moreover, they encourage researchers to explore the neural functions of TGF-βs present in 
the adult brain in other regions as well. 
3. TGF-β in Cerebral Ischemia 
The brain is highly sensitive to ischemic insult. Brain ischemia may result from stroke, heart attack, 
arterial occlusion, and virtually any type of invasive surgery. Ischemic stroke alone is one of the 
leading causes of death and a leading cause of serious, long-term disability in developed countries. 
Options for prevention and treatment are limited necessitating new approaches. One of these is TGF-β, 
a group of endogenous proteins with potential neuroprotective actions. 
3.1. The Induction of TGF-βs in Response to Brain Ischemia 
An increase in the level of TGF-β has been reported in different models of experimental brain 
ischemia. In twenty-one-day-old rats, a unilateral ligation of the right carotid artery followed by 
inhalational hypoxia resulted in selective neuronal loss in cortical layer 3 and in the hippocampus of 
the ligated hemisphere followed by TGF-β1 expression in these sites seventy-two hours after  
hypoxia [44]. Transient global ischemia also caused an elevation in TGF-β1 levels in the adult 
hippocampus. Six hours after ischemia, a diffuse expression of TGF-β1 mRNA was found throughout 
the brain, which further intensified until day 2 and thereafter subsided. In parallel, a massive increase 
of signal was observed in the hilus of the dentate gyrus and in the CA1 region. Peak levels of TGF-β1 
mRNA were found in the hilus around day 4, whereas expression in the CA1 region persisted through 
day 21 [45]. It is less well known how levels of other subtypes of TGF-βs change after ischemia.  
A study, which confirmed the induction of TGF-β1 following transient forebrain ischemia actually 
showed a decrease in the levels of TGF-β2 and -β3 in CA1 region [46] while some other studies 
reported increases in the levels of TGF-β2 and -β3, their receptors and binding proteins following 
ischemia [47,48]. The induction of TGF-β1 was also demonstrated following focal ischemic attacks. In 
rats, as well as in baboons, middle cerebral artery occlusion (MCAO) resulted in a marked expression 
of TGF-β1 in the penumbral zone that surrounded the tissue destined to infarction [16,49,50]. In fact, 
an elevated level of TGF-β1 in brain tissue was also found in human following ischemic stroke [51]. 
3.2. Cell Types Expressing TGF-βs Following Brain Ischemia 
TGF-β1 upregulation in astrocytes and microglia has been reported to be a predominant response to 
lesion and during pathology [52–54] that results in the induction of reactive phenotypes [55,56]. Under 
basal conditions, astrocytes were also shown to express TGF-β1 in some brain regions [38,57]. 
However, neuronal expression of TGF-β1 has also been reported [52,58,59]. The available data on the 
cell type specific expression of other TGF-β subtypes is scarce. However, their distributions suggest a 
dominant neuronal expression [15,16]. Following MCAO, it has been demonstrated in double labeling 
studies that activated microglia and macrophages are the major source of TGF-β1 mRNA following 
experimental focal cerebral ischemia [50,60]. However, double-staining experiments demonstrated 
increased expression of all TGF-β isoforms in astrocytes, too, suggesting that TGF-βs in astrocytes are 
also important endogenous mediators in the penumbral response to ischemic injury [46]. Furthermore, 
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a rapid up-regulation and persistent expression of TGF-β1 was found in surviving CA1 pyramidal cells 
after cerebral ischemia supporting that neurons may also contribute to the elevated TGF-β1 levels  
after ischemia [48]. 
3.3. Effect of TGF-βs on Ischemic Brain Lesion 
A neuroprotective role of the induced TGF-β1 following ischemia was suggested by its correlation 
with the reduction of the infarct area. Thus, clenbuterol, a β(2)-adrenoceptor agonist, was 
neuroprotective in the hippocampus and caused an increase in TGF-β1 expression in non-ischemic rats 
and further enhanced TGF-β1 protein levels in rat CA1 pyramidal neurons after transient forebrain 
ischemia [48]. TGF-β administration itself also decreased the size of infarction. In a rabbit model of 
thromboembolic stroke, an autologous clot embolus was introduced intracranially. TGF-β1 
administered as an intracarotid bolus immediately before autologous clot embolization reduced brain 
infarct size in a way not related to a direct effect on blood flow [61]. A similar neuroprotective action 
of exogenously applied TGF-β1 was also found following middle cerebral artery occlusion (MCAO) in 
the rat [62,63]. Furthermore, the overexpression of TGF-β1 achieved through adenoviral gene transfer 
also reduced the infarct size in mice following 30 min of MCAO and 1 to 7 days of reperfusion [64]. 
More relevantly for potential clinical applications, intranasal administration of TGF-β as a 
noninvasive method for delivery of neuropeptides into the brain to bypass the BBB, reduced infarct 
volume and improved functional recovery in mice after MCAO [65]. A more direct evidence for the 
involvement of TGF-β in endogenous neuroprotection was suggested by a study antagonizing TGF-β 
actions. Injection of a soluble TGF-β type II receptor as a TGF-β antagonist into the brain aggravated 
the volume of infarction following a 30-minute reversible cerebral focal ischemia [66]. Based on the 
available evidence, the involvement of TGF-β1 in neuroprotection against ischemia is likely. Since 
some of the experiments did not differentiate between the subtypes, a role of TGF-β2 and -β3 is also 
conceivable. The possible mechanisms include anti-inflammatory actions, promotion of scar formation, 
anti-apoptotic actions, protection against excitotoxicity, and the promotion of angiogenesis and 
neuroregeneration. These mechanisms will be discussed in Chapter 8 entitled: The neuroprotective 
mechanisms of TGF-βs. In addition, although the evidence is scarce, TGF-βs, as endogenous 
neuroprotective proteins, could participate in ischemic tolerance or preconditioning, too [67,68]. The 
mechanisms of this potential action of TGF-βs might include complex but as yet largely unexplored 
actions on the gene expression patterns of different neuronal cell types. 
4. TGF-β in Traumatic CNS Injury 
Brain and spinal cord injury continues to result in high morbidity and mortality throughout the 
world. The neural damage following traumatic injury is a result of direct or primary injury and delayed 
indirect or secondary mechanisms. An effective neuroprotective agent is still not available to 
counteract secondary damage caused by traumatic injury. TGF-β is subject of strategies to develop 
drugs that are able to reduce the indirect tissue damage [69]. 
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4.1. The Induction of TGF-βs in Response to Traumatic Injury 
An increased level of TGF-βs was found in the brain following traumatic injuries [69]. No clear 
arterio-jugular venous gradients were apparent providing evidence for the cerebral production of  
TGF-βs [70]. Indeed, the mRNA encoding TGF-β1 increased in rat cerebral cortex after a penetrating 
brain injury. A strong expression of TGF-β1 was found 4 days after the lesion in cells within and in the 
vicinity of the wound [71]. Staining of adjacent sections with an antibody specific for macrophages 
and microglia/brain macrophages revealed a similar pattern of positive cells, suggesting that invading 
macrophages, and perhaps reactive microglia, are the source of TGF-β1 in injured brain after a 
penetrating injury [71]. TGF-β expression was also investigated in a model of spinal cord injury in rats 
using an impactor. TGF-β expression increased immediately after spinal cord injury in the injured 
segment and persisted for 24 h after injury [72]. In addition to TGF-β1, TGF-β2 might also be induced 
by trauma: in a model of fluid-percussion injury, biphasic production of TGF-β2 was detected in the 
ipsilateral cortex using a bioassay, with a first peak at 30 min and a second peak at 48 h after the  
lesion [73]. 
Apart from animal models, the spatial and temporal expression patterns of TGF-β1 and TGF-β2 
were also investigated in the human spinal cord after traumatic injury using immunohistochemistry.  
In control cases, TGF-β1 was confined to occasional blood vessels, intravascular monocytes and some 
motoneurons, whereas TGF-β2 was only found in intravascular monocytes. After traumatic spinal cord 
injury, TGF-β1 immunoreactivity was dramatically upregulated by 2 days after injury and was 
detected within neurons, astrocytes and invading macrophages. The staining was most intense over the 
first weeks after injury but gradually declined by 1 year. TGF-β2 immunoreactivity was first detected 
24 days after injury. It was located in macrophages and astrocytes and remained elevated for up  
to 1 year [74]. 
The expression of receptors to TGF-βs was examined by in situ hybridization histochemistry in 
transcortical knife lesions of the striatum in the mouse brain. Type I and type II TGF-β receptor 
mRNAs were barely detected in the intact brain and first found in meningeal cells near the lesion 1 day 
postinjury. Many cells expressing TGF-β receptors were found around the lesion site 3 days postinjury, 
and some of them were immunoreactive for fibronectin. After 5 days postinjury, many fibroblasts 
migrated from the meninges to the lesion site formed the fibrotic scar, and most of them expressed 
TGF-β receptors. In contrast, few of reactive astrocytes expressed the receptors throughout the 
postinjury period examined indicating that meningeal fibroblasts not reactive astrocytes are a major 
target of TGF-β1 that is upregulated after CNS injury [17]. 
4.2. TGF-β Actions for Traumatic Injury 
Transgenic mice overexpressing TGF-β1 in astrocytes developed a severe hydrocephalus, seizures, 
and early runting [75]. While unmanipulated heterozygous transgenic mice from a low expressor line 
showed no such alterations, increasing TGF-β1 expression in this line by injury-induced astroglial 
activation or generation of homozygous offspring did result in the abnormal phenotype. 
Overexpression of TGF-β1 gene by adenoviral delivery into guinea pig cochleae 4 days prior to 
injecting an ototoxic dose of aminoglycosides resulted in better hearing and fewer missing inner hair 
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cells. Cochleae with TGF-β1 overexpression exhibited fibrosis in the scala tympani suggesting that the 
adenovirus-mediated overexpression of TGF-β1 can be used to protect cochlear hair cells and hearing 
from ototoxic trauma [76]. 
The area of secondary damage around a traumatic injury has similarity to the ischemic penumbra 
suggesting a neuroprotective action of TGF-βs in this area. While some evidence is indeed available 
for such a role of TGF-βs (discussed above), further work is required for establishing and utilizing this 
function of TGF-βs for traumatic brain injuries. 
5. TGF-β in Multiple Sclerosis 
Multiple sclerosis (MS) is characterized by multiple symptoms of brain and spinal cord dysfunction 
that reflect degeneration of particular areas of the nervous system that are involved. The affected 
regions vary between patients and are not specific to the disease. The pathological hallmark is 
inflammatory demyelination and axonal lesions. Inflammation is primarily driven by autoreactive 
lymphocytes, which recruit immune cells, such as macrophages, causing tissue damage [77–79].  
Experimental autoimmune encephalomyelitis (EAE) is the most widely accepted animal model of 
MS. Different types of EAE have been developed in order to investigate pathogenetic, clinical and 
therapeutic aspects of the heterogenic human disease [80]. EAE is characterized by the activation of 
immune cells, demyelination of axons in the CNS, and paralysis. 
5.1. The Expression Level of TGF-βs in EAE and MS 
TGF-β1 synthesis in glial cells and TGF-β induced signaling in the CNS were activated several 
days before the onset of paralysis in mice with autoimmune encephalomyelitis. While early production 
of TGF-β1 was observed in glial cells TGF-β signaling was activated in neurons and later in 
infiltrating T cells in inflammatory lesions [81]. In actively induced EAE, in situ hybridization 
revealed strong expression of TGF-β1 in meningeal and perivascular mononuclear infiltrates at onset 
of the disease, continued expression in perivascular infiltrates and scattered mononuclear cells at 
maximal disease severity, and expression in scattered parenchymal cells during recovery [82]. Double 
labeling studies revealed subpopulations of infiltrating T-cells to be the major source of TGF-β1 early 
in the disease, followed by macrophages at peak severity and microglial cells during the recovery 
phase EAE. Astrocytes and neurons did not express TGF-β1. TGF-β1 expressed early in the disease by  
T-cells may contribute to inflammatory lesion development, microglial cells may potentially contribute 
to recovery by expressing immunosuppressive TGF-β1 during remission [82]. 
Apart from experimental animal models, TGF-β1 was also found to be elevated in MS patients. 
Using an anchorage-independent growth assay for TGF-β, an increased activity was detected in the 
supernatants from blood cell cultures from patients with MS in an early study [83]. MS was also 
associated with increased TGF-β mRNA expressing cells in blood [84,85]. However, more recent 
studies found a reduced level of TGF-β1 in the serum of MS patients [86]. Furthermore, in a  
pathway-focused expression profiling of the peripheral blood, reduction in the levels of TGF-β 
regulated genes was found indicating an overall reduction in TGF-β signaling in MS [87]. Overall, the 
analysis of TGF-β in blood resulted in controversial data. Furthermore, the examination of 
cerebrospinal fluid is more valuable in the context of MS. First, routine diagnostic evaluation of 
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cerebrospinal fluid cell counts and various forms of immunoglobulin determination are important to 
differentiate MS from other diseases. Second, because MS is an organ-specific inflammatory disease 
and cerebrospinal fluid is often the closest one can get to the target organ [88]. TGF-β levels in 
cerebrospinal fluid of MS patients were significantly higher in remission than in the active phase [89]. 
Biologically active TGF-β1 in cerebrospinal fluid correlated positively with the duration of the acute 
relapse in patients with primary-relapsing MS. The more relapses the patients had the higher the 
biologically active TGF-β1 was in cerebrospinal fluid [86]. In perivascular and parenchymal 
macrophages and in hypertrophic astrocytes a strong to intense immunoreactivity was apparent for all 
3 TGF-β isoforms and their receptors in active demyelinating MS lesions [90]. 
5.2. The Effects of TGF-βs in EAE and MS 
TGF-β1, injected daily for 1–2 weeks, protected against relapsing experimental allergic 
encephalomyelitis, the animal model of MS. When administered during induction of the disease,  
TGF-β1 delayed the onset of relapsing experimental allergic encephalomyelitis. However, when 
administered during a remission, TGF-β1 prevented the occurrence of relapses in relapsing experimental 
allergic encephalomyelitis [91]. This effect of TGF-β1 may be based on its ability to selectively 
suppress autoantigen-induced upregulation of pro-inflammatory cytokines [92]. Alternatively, TGF-β1 
acts on oligodendrocyte development by modulating the growth factor repertoire in MS to promote 
remyelination [93]. Nasal administration of TGF-β1 to EAE mice improved clinical EAE. The 
development and relapse of protracted-relapsing EAE in rats were inhibited [94]. Later, it has been 
suggested that TGF-β1-induced suppression of EAE is associated with apoptosis of CD4+ T cells [95]. 
However, TGF-β1 may also have actions that are not beneficial in MS. TGF-β enhanced the capability 
of myelin basic protein-specific Lewis rat T cell lines to transfer EAE [96]. TGF-β1 also re-induced 
Jagged1 in astrocytes and thereby inhibited process outgrowth from primary human oligodendrocytes 
[97]. Jagged I is a ligand of the Notch1 receptor whose signaling regulates oligodendrocyte progenitor 
differentiation and myelin formation in development, and during remyelination in the adult CNS [98]. 
Furthermore, systemic treatment with a pharmacological inhibitor of TGF-β signaling ameliorated the 
paralytic disease [81]. Thus, early production of TGF-β1 in the CNS may create a permissive and 
dangerous environment for the initiation of autoimmune inflammation. 
5.3. Genetic Studies on the Involvement of TGF-βs in MS 
Genome screenings in multiple sclerosis (MS) have identified multiple susceptibility regions 
supporting a polygenic model for this disease. Evidence for linkage was observed at chromosome 
19q13 suggesting the presence of an MS gene(s) in this region encoding TGF-β1. A comprehensive 
evaluation of common polymorphisms within the TGF-β1 was performed in MS families. Distinct 
clinical phenotypes were also examined and an association between a TGF-β1 haplotype and a mild 
disease course was present raising the possibility that TGF-β1 may influence disease expression [99]. 
However, another study did not find the genetic variation in TGF-β1 as a major factor to susceptibility 
to MS [100]. In turn, a recent study identified a TGF-β1 genotype with higher frequency in patients 
suggesting that this polymorphism may play a role in susceptibility to MS [101]. 
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5.4. TGF-β Subtypes in MS 
The potential role of TGF-β subtypes other than TGF-β1 in MS received much less attention. The 
available data suggest that acute active lesions exhibit selective TGF-β2 immunoreactivity in ramified 
microglia encircling the lesion. In contrast, astrocytes within chronic active white matter lesions 
expressed all three subtypes. Chronic active lesions extended into cortex exhibited selective cortical 
astrocyte TGF-β2 expression, which suggests that TGF-β cytokines are locally expressed in 
demyelination and that TGF-β2 may be uniquely regulated [102]. However, an indirect association 
analysis of TGF- β2 using 8 haplotype-tagging SNPs in a population of 937 MS patients and 2022 
controls did not find evidence for association with susceptibility or progression of MS [103]. Thus,  
it seems likely that TGF-β1 is the major TGF-β subtype involved in MS and other subtypes may play 
only minor roles in the disease. 
6. TGF-β in Neurodegenerative Disorders 
Neurodegenerative diseases include a group of illnesses that are characterized by a progressive loss 
of neuronal populations in the CNS. On the basis of the distribution of the degenerating neurons, the 
illnesses can be classified as diffuse or generalized atrophy, such as Alzheimer’s disease, or a  
system-specific atrophy, e.g., Parkinson’s and Huntington’s disease. The pathogenesis of 
neurodegenerative cell losses is largely unknown [104]. Substantial evidence suggests the involvement 
of TGF-βs in Alzheimer’s and Parkinson’s diseases, which will be the subject of this chapter. 
6.1. Alzheimer’s Disease  
Alzheimer’s disease is a progressive, degenerative disease of the brain that is the most common 
cause of dementia in the elderly. Typical pathological features of Alzheimer’s disease (AD) are 
neuritic plaques and neurofibrillary tangles occurring primarily in the cholinergic basal forebrain and 
the hippocampus, frontal, parietal and temporal lobes of the cerebral cortex. AD is characterized by the 
presence of beta-amyloid (Aβ) plaques, neurofibrillary tangles, and neuronal loss. Current drugs for 
AD are only symptomatic, but do not interfere with the underlying pathogenic mechanisms of the 
disease. The identification of the molecular determinants underlying AD pathogenesis is a fundamental 
step to design new disease-modifying drugs [105]. An increasing amount of evidence suggests a 
neuroprotective role for TGF-β1 against Aβ toxicity both in vitro and in vivo models of AD [106]. 
6.1.1. TGF-β Levels in AD and Its Animal Models 
In mouse models of AD, the expression level of TGF-β1 is increased [107]. In the brains of patients 
with AD, an increased expression of TGF-β2 was demonstrated [108]. Furthermore, a significant 
increase in TGF-β1 mRNA expression level in AD patients was found before the manifestation of 
overt dementia suggesting that it is mobilized in the developmental course of AD pathology [109]. 
TGF-β1 expression levels correlate with the degree of cerebrovascular amyloid deposition in AD and 
TGF-β1 immunoreactivity in such cases is increased along the cerebral blood vessels [110]. Although 
the mechanisms of induction of TGF-β1 are not fully established, acidosis might play a role.  
A fourfold TGF-β1 bioactivity with decreased intracellular TGF-β1 precursor (latency associated 
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protein-TGF-β1) was found in primary hippocampal cell cultures kept at a mildly acidic pH 
characteristic of the chronic inflammation accompanying AD [111]. In contrast to the increase in the 
levels of TGF-βs, the levels of TGF-β type II receptor is reduced in neurons of human AD brain in 
correlation with pathological hallmarks of the disease [112]. This finding suggests that the 
overproduction of TGF-β could also be a compensatory mechanism in AD. 
6.1.2. The Role of TGF-βs in AD Progression 
The attenuation of Aβ neurotoxicity at a pH mildly acidic to the physiological pH was shown to be 
mediated by the increased activation and signaling of TGF-β [111]. Another potential neuroprotective 
action of TGF-βs is their effect on the invasion of immune cells from the circulation. While local 
recruitment of brain microglia to sites of amyloid deposition fail at restricting β-amyloid plaque 
formation, it is becoming increasingly clear that professional phagocytes from the periphery possess 
Aβ clearance aptitude. TGF-β Smad 2/3 signaling impacts blood-to-brain trafficking of these cells in 
transgenic mouse models of AD [113]. AD mice that are deficient in peripheral mononuclear 
phagocyte TGF-β signaling have increased microglia accumulation around β-amyloid plaques and 
reduced AD-like pathology [114]. Mice overexpressing TGF-β1 lead to a reduction in macrophage 
activity and migration ability. Furthermore, pre-incubation of endothelial cells with TGF-β1 reduced 
the ability of endothelial cells to stimulate macrophage activity [115]. Thus, regulating microglia 
recruitment into the brain is a potential therapeutic strategy to delay or stop the progression of AD. 
Chronic overproduction of TGF-β1 triggers a pathogenic cascade leading to AD-like cerebrovascular 
amyloidosis, microvascular degeneration, and local alterations in brain metabolic activity. AD is 
frequently associated with these alterations suggesting that TGF-β1 contributes to the development of 
AD [116]. However, in aged transgenic mice featuring astrocytic TGF-β1 overexpression, neuronal 
and cognitive indices—the stimulus-evoked neurometabolic response, cortical cholinergic innervation, 
and spatial memory in the Morris water maze—were intact suggesting that impaired brain 
hemodynamics and cerebrovascular function are not accompanied by memory impairment in this 
model [117]. In turn in mice overproducing both Aβ and TGF-β1 peptides, an early progressive 
decline in cerebrovascular dilatory ability, and a reduction in constitutive nitric oxide synthesis was 
found. These mice featured deficient neurovascular and neurometabolic coupling to whisker 
stimulation, cholinergic denervation, cerebral and cerebrovascular Aβ deposition, astrocyte activation, 
and impaired Morris water maze performance, which gained severity with age [118]. These data 
suggest that under some circumstances, TGF-β1 could be a factor that contributes to the progress of 
AD rather than protects against it. TGF-β1 overexpressing mice were also used to test potential 
treatments for AD. A nasally administered proteosome-based adjuvant activating macrophages and 
decreasing vascular amyloid formation was administered on a weekly basis for 3 months beginning at 
age 13 months in TGF-β1 overexpressing mice. Using magnetic resonance imaging (MRI), control 
animals were demonstrated to have a significant cerebrovascular pathology. In turn, proteosome-based 
adjuvant prevented further brain damage and pathological changes in the blood-brain barrier and a 
significant improvement in cognition [110]. It is possible, that the chronic overexpression of TGF-β 
results in physiological artifacts leading to contradictory data on the neuroprotective role of TGF-β1 in 
AD as a modest increase in astroglial TGF-β1 production in aged transgenic mice expressing the 
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human beta-amyloid precursor protein resulted in a reduction in the number of parenchymal amyloid 
plaques in the hippocampus and cerebral cortex, and decreased the number of dystrophic neurites [119]. 
Apart from the evidence listed above, genetic studies also support the involvement of TGF-β1 in 
AD pathogenesis as a specific genotype of the TGF-β1 gene increased the risk to develop the 
depressive symptoms associated with AD [120]. So far, the role of TGF-β1 was almost exclusively 
studied in AD while the involvement of other types of TGF-βs cannot be excluded and their 
examination should be included in future studies. Apolipoprotein E4, the most prevalent genetic risk 
factor of Alzheimer's disease, reduced the levels of TGF-β1, -β2, as well as -β3 in the septum and that 
of TGF-β3 in the hippocampus suggesting the possible role of different TGF-βs in mediating the 
pathological effects of apolipoprotein E4 [121]. 
6.1.3. TGF-β Signaling in AD 
Deficiency of TGF-β signaling seems to be an early event in AD pathogenesis [106]. An elevated 
level of phosphorylated Smad2 was found in hippocampal neurons of AD brains. However, in contrast 
to an expected nuclear localization, phosphorylated Smad2 in Alzheimer’s disease was predominantly, 
and ectopically, found in the neuronal cytoplasm, specifically colocalized with neurofibrillary tangles 
and granulovacuolar degeneration [122,123]. In cultured cells, reduced TGF-β signaling caused 
neuronal degeneration and resulted in increased secretion of Aβ [112]. Reduced TGF-β1 signaling 
seems to contribute both to microglial activation and to ectopic cell-cycle re-activation in neurons, two 
events that contribute to neurodegeneration in the AD brain. Even the direct binding of Smad proteins 
to the CDK4 promoter inducing transcriptional inhibition of cell cycle-dependent kinase 4 has recently 
been identified [124]. The neuroprotective features of TGF-β1 indicate the advantage of rescuing  
TGF-β1 signaling as a means to slow down the neurodegenerative process in AD [125].  
6.2. Parkinson’s Disease 
The initiation of movement is governed by the interaction of the motor cortex, the thalamus, and a 
circuit consisting of several members of the basal ganglia, including the striatum, globus pallidus and 
substantia nigra. The underlying pathology for Parkinson’s disease (PD) is the loss of nigrostriatal 
dopaminergic cells projecting to the striatum [126]. There is ample evidence that TGF-βs promotes the 
survival of dopaminergic neurons in the substantia nigra. 
6.2.1. TGF-β Levels and Their Alterations in PD 
TGF-β2 and -β3 could be detected in freshly isolated and cultured mesencephalic cells [127]. 
Furthermore, lesioning of the mouse nigrostriatal system with 1-metil-4-fenil-1,2,3,6-tetrahidropiridin 
(MPTP) significantly upregulated TGF-β2 mRNA levels in the striatum [128]. These data suggest that 
endogenous TGF-βs are available to affect the survival of dopaminergic neurons in the  
substantia nigra. 
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6.2.2. The Effect of TGF-β on the Survival of Dopaminergic Neurons in the Substantia Nigra 
TGF-βs were shown to promote the in vitro survival of tyrosine hydroxylase (TH)-immunoreactive 
dopaminergic neurons isolated from the embryonic rat mesencephalon floor. TGF-βs also protected 
dopaminergic neurons against N-methyl-4-phenylpyridinium ion toxicity [127]. It has also been 
demonstrated that the effects of TGF-βs on dopaminergic cells was neither mediated by astroglial cells 
nor accompanied by an increase in cell proliferation [129,130]. Treatment of cells dissociated from 
midbrain floor with TGF-β significantly increased the number of TH-positive dopaminergic neurons 
within 24 h. Neutralization of TGF-β in vitro completely abolished the induction of dopaminergic 
neurons [131].  
Neutralizing endogenous Sonic hedgehog protein abolishes the capacity of TGF-β to induce 
dopaminergic neurons in vitro. In turn, Sonic hedgehog cannot induce TH-positive neurons in the 
absence of TGF-β suggesting an interaction between these factors in the development of TH  
neurons [131]. The interaction of TGF-βs with other factors regarding the development and survival of 
mesencephalic dopaminergic cells has also been extensively investigated. Co-localization of the 
receptors for TGF-β and glial cell line-derived neurotrophic factor (GDNF) was found. Moreover, the 
relevance of the TGF-β/GDNF synergism is highlighted by the co-storage of TGF-β and GDNF in 
secretory vesicles of a model neuron, the chromaffin cell, and their activity-dependent release [132]. 
GDNF was a potent survival factor for these dopaminergic neurons in culture [133]. Application of 
antibodies neutralizing TGF-β isoforms abolished the neurotrophic effect of GDNF suggesting that 
TGF-β may be essential for permitting exogenous GDNF to act as a neuroprotective factor [128].  
In turn, GDNF rescued the TGF-β neutralization-dependent loss of the TH-positive cells after 8 days  
in vitro suggesting that TGF-β is required for the induction of dopaminergic neurons, whereas GDNF 
is required for regulating and/or maintaining a differentiated neuronal phenotype [134]. TGF-β also 
interacts with neurturin and persephin (PSPN), which are also capable of transient induction of 
dopaminergic neurons [134]. In vitro, combined TGF-β/PSPN treatment achieved a yield of 
approximately 20% TH-positive cells that were less vulnerable against 1-methyl-4-phenyl pyridinium 
ion toxicity suggesting that the combination of TGF-β with PSPN is a potent inductive cocktail for the 
generation of dopaminergic neurons [135]. It has also been demonstrated that the transcriptional 
cofactor homeodomain interacting protein kinase 2 (HIPK2) is required for the TGF-β mediated 
survival of mouse dopaminergic neurons. The targeted deletion of Hipk2 has no deleterious effect on 
the neurogenesis of dopaminergic neurons, but leads to a selective loss of these neurons that is due to 
increased apoptosis during programmed cell death. The function of HIPK2 depends on its interaction 
with receptor-regulated Smads to activate TGF-β target genes. Dopaminergic neurons from Hipk2(−/−) 
mutants fail to survive in the presence of TGF-β3. Furthermore, TgF-β3(−/−) mutants show 
dopaminergic neuron abnormalities similar to those seen in Hipk2(−/−) mutants [136]. The 
neuroprotective function of TGF-β2 has also been shown against the neurotoxin 6-hydroxydopamine, 
which induces a Parkinson-like neurodegeneration. A microglial conditioned medium nearly completely 
protected cerebellar granule neurons challenged with 6-hydroxydopamine. While the fraction of the 
medium containing molecules <30 kDa completely protected cerebellar granule neurons, fractions 
containing molecules <10 kDa were not neuroprotective. The exogenous addition of TGF-β2 to the 
fraction of the medium not containing it (<10 kDa) fully restored the neuroprotective action. 
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Moreover, the neuroprotection was significantly counteracted by an inhibitor of TGF-β2 transduction 
pathway [137]. 
In vivo evidence also suggests the involvement of TGF-βs in PD. Neutralization of TGF-β in vivo at 
a critical period resulted in a significant reduction in TH-positive neurons in the ventral midbrain floor 
but not in the locus coeruleus or diencephalon suggesting that TGF-β is required for the induction of 
mesencephalic dopaminergic neurons. Furthermore, neutralization of TGF-β at a later time period 
during maturation of mesencephalic dopaminergic neurons when no further inductive cues are 
required, also resulted in a significant loss of dopaminergic neurons [131]. Interestingly, no apparent 
phenotype concerning dopaminergic neurons was observed in TGF-β2 single mutant [138] and  
Tgf-β2(−/−)/gdnf(−/−) double mutant mice [134]. In turn, in adult mice deficient in Smad3, a molecule 
involved in the intracellular TGF-β1 signaling cascade, dopaminergic neuronal degeneration was 
found in the rostral portion of the substantia nigra [139].  
Neural transplantation is developing into a therapeutic alternative in Parkinson’s disease. A major 
limiting factor is that only 3–20% of grafted dopamine neurons survive the procedure. Different 
approaches may be able to reduce cell death and increase survival of grafted neurons. TGF-βs are 
among other growth factors that may provide hope for improved survival of transplanted neurons in 
patients with Parkinson's disease, reducing the need for human embryonic donor tissue and increasing 
the likelihood of a successful outcome [140]. 
7. TGF-β in Neurodegeneration Resulted from Brain Infections 
A variety of brain infections lead to lesions of neuronal tissue. These lesions represent diverse 
mechanisms as pathogens operate with individual strategies. Encephalitis is most frequently caused by 
viruses but could also be elicited by bacteria. Rabies, polio, and herpes viruses infect neurons, 
however, some other viruses attack primarily glial cell types [104]. In some infections, TGF-βs protect 
against collateral damages caused by the immune system, however, they may promote immune evasion 
and chronic infections in other cases [141]. 
Borna disease is a virus-induced, immune-mediated encephalomyelitis based on a delayed-type 
hypersensitivity reaction. Infection with borna disease virus increased the expression of TGF-β in the 
brain of rats. An up-regulation of TGF-β expression was found in the brain, while the expressions of 
signal receptors for TGF-β1 were also increased suggesting that members of the TGF-β family are 
involved in neuronal disorders induced by borna disease virus infection [142]. The severity of clinical 
symptoms after intracerebral infection of rats with Borna disease virus was reduced after treatment 
with TGF-β as continuous intraperitoneal injection. The inhibition of the disease was paralleled by a 
significant reduction of the inflammatory reaction in the brain [143]. 
For other viruses, TGF-βs could actually contribute to the infections. Rabies virus causes a non-lytic 
infection of neurons leading to a fatal myeloencephalitis in mammals including humans. Rabies virus 
avoids induced neuron cell death. In contrast, T cells that migrate into the infected nervous system are 
killed by apoptosis and inflammation of the infected nervous system is limited [144]. The examination 
of brain tissue from patients with cytomegalovirus encephalitis showed co-localization of 
cytomegalovirus inclusions and TGF-β in cells that contained astrocyte-specific glial filaments.  
In an ex vivo murine model of cytomegalovirus-infected astrocytes, the inoculated cells increased the 
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amounts of infectious cytomegalovirus in parallel with increasing levels of TGF-β mRNA and peptide. 
Astrocyte release of cytomegalovirus declined in the presence of antibody to TGF-β and increased 
substantially after the addition of exogenous TGF-β suggesting that cytomegalovirus infection of 
astrocytes induces the production of TGF-β, which in turn enhances productive cytomegalovirus 
expression [145]. Progressive multifocal leukoencephalopathy is a fatal demyelinating disease of the 
CNS. JC virus (JCV), a human neurotropic polyomavirus, is the etiologic infectious agent of this 
disease. High levels of TGF-β1 and Smads 3 and 4 were detected in JCV-infected oligodendrocytes, 
which augment the transcription of the JCV promoter in glial cells [146]. 
Infection by human immunodeficiency virus type 1 (HIV-1) is often complicated with a high 
incidence of neurologic disorders. By attacking immune cells, HIV-1 infections have special usage of 
TGF-βs. It is believed that HIV-1, in addition to infecting both macrophage and microglial cells, may 
also influence the expression of several strategic genes of uninfected neighboring or latently infected 
brain cells. The HIV-1 Tat protein was demonstrated to increase the expression of TGF-β1 and 
possibly also its receptor [147–149]. In the cerebrospinal fluid of patients with HIV-1 infection,  
TGF-β1 level was also significantly elevated [150]. Tat is a transcription transactivator produced by 
HIV-1 at the early phase of infection and plays a critical role in the expression and replication of the 
viral genome. This 86 amino acid protein, which can be secreted from the infected cells, has the ability 
to enter uninfected cells and exert its activity upon the responsive genes. In addition to the HIV-1 
promoter, Tat has the capacity to induce transcription of a variety of cellular genes including  
TGF-βs [148]. In particular, the expression of TGF-β1 in ameboid microglia may play a role in HIV-1 
neuropathogenesis [151]. In turn, TGF-β1 may control HIV-1 expression in the brain and astrocytosis, 
the two hallmarks of brain in AIDS patients [152]. In later stages of HIV-1 infection as microglial cells 
deteriorate, HIV-RNA is in inverse proportion to TGF-β1. Furthermore, in patients with severe  
AIDS-dementia, TGF-β1 is undetectable [153]. 
Bacterial infections may also lead to increased TGF-β levels. In the cerebrospinal fluid of patients 
with bacterial meningitis, a high level of TGF-β1 mRNA was detectable in the cell populations [154]. 
Although peripheral infections may also lead to increased TGF-β levels in the brain e.g., associated 
with fever [155], its brain origin has also been proved: injection of bacterial lipopolysaccharide in the 
right dorsal hippocampus to mimic cerebral bacterial infection resulted in an increase in TGF-β1 
expression 24 h after the injection [67]. TGF-β was suggested to prevent the microvascular changes 
associated with brain edema formation in bacterial meningitis, a major intracranial complication 
leading to brain damage based on its effect to interfere with bacterially induced tumor necrosis factor 
alpha production, oxygen radical formation and the adhesiveness of granulocytes to endothelial  
cells [156]. There are, however, some contradictory data available on the role of TGF-β in edema 
formation. In mice with Streptococcus pneumoniae-induced meningitis, a deletion of TGF-β  
receptor II on leukocytes was found to prevent meningitis-induced vasculitis [157]. 
8. The Role of TGF-βs in Brain Tumors 
High-grade gliomas are the most common primary tumors in the central nervous system (CNS) in 
adults. Since TGF-β is intimately involved in the regulation of several processes characteristic of 
human malignant glioma including excessive proliferation, infiltrative growth, angiogenesis and 
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suppression of anti-tumor immune surveillance, TGF-β promises to become a novel target for the 
experimental therapy of human malignant glioma [158]. 
8.1. Proliferative Actions of TGF-βs in Brain Tumors 
TGF-βs possess anti-proliferative control on most cell types including astrocytes. Cultured 
astrocytes demonstrated a significant decrease in DNA synthesis in response to TGF-β and were 
arrested in the G(1) phase of the cell cycle with an up-regulation of the cyclin-dependent kinase 
inhibitor (CdkI) p15 [159]. Furthermore, astrocytes from Smad3 null mice demonstrated a reduced 
TGF-β-mediated inhibition of growth suggesting the involvement of the Smad signal transduction 
pathway [159].  
High-grade human gliomas secrete TGF-β and can activate latent TGF-β [160]. Yet, they are 
resistant to its growth inhibitory effects as they develop mechanisms that change the anti-proliferative 
influence of TGF-β into oncogenic cues. Consequently, TGF-β may be involved in the progression of 
brain tumors [24]. The dominant hypothesis of TGF-β’s pathogenetic association with malignant 
transformation has been predicated upon acquisition of resistance to its growth inhibitory effects but 
the existence of intrinsically opposed regulatory mechanisms influenced by TGF-β are also 
conceivable [161]. The mechanism of conversion might be explained either by the loss of a putative 
tumor suppressor gene, which mediates TGF-β’s inhibition of growth or by enhancement of an active 
oncogenic pathway among hyperdiploid glioblastoma multiforme. The expression of the Smad2 and 
Smad3 proteins is reduced in many glioma cell lines. The phosphorylation and nuclear translocation of 
Smad2 and Smad3 are also impaired [162]. The loss of p15(INK4B) may also explain the selective 
loss of growth inhibition by TGF-β in gliomas to form a more aggressive tumor phenotype [159]. 
TGF-β also induced expression of Sox2, a stemness gene, and this induction was mediated by Sox4, a 
direct TGF-β target gene. Inhibitors of TGF-β signaling drastically deprived tumorigenicity of 
glioblastoma cells identifying the relevance of the TGF-β-Sox4-Sox2 pathway, too [163]. 
Among TGF-β isoforms, TGF-β2 has been identified as the most important factor in the progression 
of malignant gliomas. TGF-β2, originally described as “glioblastoma-derived T-cell suppressor 
factor”, was particularly associated with the immuno-suppressed status of patients with glioblastoma. 
Furthermore, elevated TGF-β2 levels in tumors and in the plasma of patients have been associated with 
advanced disease stage and poor prognosis [164]. 
8.2. The TGF-β System in the Treatment of Brain Tumors 
A variety of different in vitro paradigms and rodent glioma models demonstrated that the 
antagonism of TGF-β holds promise for the treatment of glioblastoma. In particular antisense 
strategies, inhibition of pro-TGF-β processing, scavenging TGF-β by decorin, or blocking TGF-β 
activity by specific TGF-β receptor I kinase antagonists have been tested [165,166]. Among these 
possibilities, the antisense oligonucleotide trabedersen (AP 12009) that specifically blocks TGF-β2 
mRNA has the highest potential at present to treat gliobastomas [164]. In addition, the inhibition of 
TGF-β may also be used as a supplementary treatment as it has the potential to enhance the therapeutic 
efficacy of glioma-associated antigen vaccines [167]. 
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9. The Neuroprotective Mechanisms of TGF-βs 
The mechanisms how TGF-βs exert their neuroprotective functions remain to be elucidated. There 
are, however, several plausible possibilities based on the reported actions of TGF-βs. 
9.1. Anti-Inflammatory Action 
Lesions in the CNS destroy the blood-brain barrier and provoke the invasion of hematogenous cells 
into the neural tissue. Invading leukocytes, macrophages and lymphocytes secrete various cytokines 
that induce an inflammatory reaction in the injured CNS and result in local neural degeneration, 
formation of a cystic cavity and activation of glial cells around the lesion site [168]. Some T helper 1 
cytokines such as interferon-gamma, lymphotoxin and tumor necrosis factor have been implicated in 
driving the immunopathological processes whereas some T helper 2 cytokines, e.g. TGF-βs and 
interleukin-10 oppose them [169]. TGF-β protects against collateral damages caused by the immune 
system, by acting as a potent immune suppressor through inhibition of proliferation, differentiation, 
activation, and effector function of immune cells. Paradoxically, TGF-β may also display  
pro-inflammatory properties by promoting immune evasion as potent chemoattractant for  
neutrophils [141]. Within the brain, microglial cells, the brain homologues of macrophages, are also a 
major source of these cytokines. Activation of microglia is a hallmark of brain pathology. The 
inflammatory response is mediated by the activated microglia, the resident immune cells of the CNS, 
which normally respond to neuronal damage and remove the damaged cells by phagocytosis. However, 
it remains controversial whether microglial cells have beneficial or detrimental functions in various 
neuropathological conditions [170]. The chronic activation of microglia may in turn cause neuronal 
damage through the release of potentially cytotoxic molecules such as pro-inflammatory cytokines, 
reactive oxygen intermediates, proteinases, and complement proteins [171]. TGF-βs were reported to 
inhibit microglial cells, and thereby exert an anti-inflammatory action. Since microglial cells are a 
major source of TGF-β1 in the CNS [172], they might exert an auto-inhibitory control on microglial 
cells [69]. 
Pathological examination of TGF-β1 null mice revealed an excessive inflammatory response with 
massive infiltration of lymphocytes and macrophages in many organs suggesting a prominent role for 
TGF-β1 in homeostatic regulation of immune cell proliferation and extravasation into tissues [173]. In 
turn, transgenic mice that overexpressed bioactive TGF-β1 in the CNS were more susceptible to the 
immune-mediated experimental autoimmune encephalomyelitis. TGF-β1 transgenic mice showed an 
earlier onset of clinical symptoms, more severe disease, and increased mononuclear cell infiltration 
demonstrating that local expression of TGF-β1 within the brain parenchyma can enhance immune cell 
infiltration and intensify the CNS impairment resulting from autoimmune responses [174]. 
Overexpression of TGF-β1 can downregulate the expression of some inflammatory proteins suggesting 
that the neuroprotective effect of TGF-β1 may result from the inhibition of chemokines during brain  
injury [64]. The anti-inflammatory action of TGF-β2 has also been suggested. In degenerating optic 
nerves, astrocytes strongly and continuously expressed TGF-β2 immunoreactivity. Furthermore,  
TGF-β2 suppressed spontaneous myelin phagocytosis by microglia/macrophages in a mouse ex vivo 
assay of Wallerian degeneration [175]. The anti-inflammatory actions of TGF-βs may also provide the 
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basis for the effect of TGF-β to prevent the microvascular changes associated with brain edema 
formation [156]. 
9.2. Scar Formation 
A brain injury is followed by a cascade of cellular and molecular mechanisms resulting in a 
secondary injury. To isolate the damaged tissue scar formation takes place in the injured brain. In the 
process of the fibrotic scar formation, meningeal fibroblasts invade and proliferate in the lesion site to 
secrete extracellular matrix proteins, such as collagen and laminin. Thereafter, end feet of reactive 
astrocytes elaborate a glia limitans surrounding the fibrotic scar [17]. Astrogliosis, whereby astrocytes 
in the CNS become reactive in response to tissue damage, is a prominent process leading to the 
formation of the glial scar that inhibits axon regeneration after CNS injury. Upon becoming reactive, 
astrocytes undergo various molecular and morphological changes including upregulating their 
expression of GFAP and chondroitin sulfate proteoglycans as well as other molecules that are 
inhibitory to axon growth [176]. Astrolyosis has dual effects on the restoration of neuronal function. 
Isolating the injured brain tissue may help to prevent the extension of its damaging effects on the 
healthy tissue. However, gliosis also hinders the reinnervation of the area thereby preventing regaining 
its functions. TGF-β1 has been implicated in the formation of the fibrotic scar and glia limitans. Many 
cells expressing TGF-β receptors were found around the lesion site 3 days postinjury, and some of 
them were immunoreactive for fibronectin [17]. TGF-βs also promote astrogliosis by contributing to 
the activation of astrocytes around a lesion. The growth of cultured brainstem astrocytes was 
significantly enhanced by exposure to TGF-β1 [177]. In a three-dimensional in vitro model of neurons 
and astrocytes within a bioactive matrix, TGF-β1 induced robust astrocyte hypertrophy and increased 
expression of glial fibrillary acidic protein and chondroitin sulfate proteoglycans [178]. Moreover, 
local injection of TGF-β antagonists into cerebral wounds reduced glial scarring [179–181]. The 
cellular localization and temporal pattern of expression of TGF-βs after spinal cord injury suggested 
that TGF-β2 may also participate in scar formation [182]. 
As far as the mechanism of TGF-βs induction, the blood protein fibrinogen as well as serum 
albumin were implicated, which leak into the CNS immediately after blood-brain barrier disruption or 
vascular damage [168,183]. Fibrinogen can activate the latent TGF-β complex and induce 
phosphorylation of Smad2 in astrocytes. Depletion of fibrinogen in mice reduces active TGF-β, Smad2 
phosphorylation, and glial cell activation brain injury. Furthermore, stereotactic injection of fibrinogen 
into the mouse cortex is sufficient to induce astrogliosis [184]. In addition to vascular injury, TGF-β1 
may also play a role in gliosis in degenerative diseases, which include extensive activation of 
astrocytes. TGF-β1 secreted by microglial cells and invading macrophages has been correlated with 
the reactive astrocyte phenotype and glial scar formation in multiple sclerosis [185]. The action of 
TGF-β on astrogliosis may be mediated by additional factors including connective tissue growth  
factor [186], TGF-β-inducible gene-h3, a protein secreted from reactive astrocytes at the site of a stab 
wound [187], and adenine nucleotide translocator 1, an inner mitochondrial membrane protein 
involved with energy mobilization during oxidative phosphorylation and upregulated by TGF-β in 
reactive astrocytes [188]. 
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9.3. Anti-Apoptotic Property 
Cells undergoing apoptosis exhibit very different morphological characteristics and temporal 
profiles of change from cells undergoing necrosis. Apoptosis has been identified with the 
internucleosomal fragmentation of DNA. More importantly, apoptosis has been associated with a 
process of programmed cell death, in which a genetic program is activated which results in the death of 
the cell [189]. Apoptosis enables the balance between growth and elimination of cells and occurs 
physiologically during the embryonic development or involution processes. Furthermore, infectious 
agents and other cell-damaging circumstances can lead to apoptosis. Neurons in the penumbra that 
regained their neuronal functions following ischemia may demonstrate a delayed death by apoptotic 
processes. Similarly, neurons in tissue undergoing secondary damage around a traumatic lesion may 
also dye by apoptosis. An increased rate of cell death in the adult nervous system underlies 
neurodegenerative disease and is a hallmark of multiple sclerosis, Parkinson’s and Alzheimer’s  
disease [190]. Therefore, anti-apoptotic agents were suggested to promote neuronal survival in a 
variety of pathological conditions [191]. 
TGF-βs were shown to inhibit apoptosis. TGF-β1 has also been characterized as an anti-apoptotic 
factor in a model of staurosporine-induced neuronal death through a mechanism involving activation 
of the extracellular signal-regulated kinase 1/2 [192] and an inhibition of caspase 3 [193].  
Anti-apoptotic action of TGF-β1 on neurons has also been suggested in the dentate gyrus of adult rats 
following adrenalectomy [194]. The anti-apoptotic property of TGF-βs may contribute to their 
neuroprotective actions [192]. After adenovirus-mediated TGF-β1 transduction under non-ischemic 
and ischemic conditions induced by transient middle cerebral artery occlusion, a gradual activation of 
extracellular signal-regulated kinase 1/2 (Erk1/2) and MAPK-activated protein kinase-1 was found as 
well as a concomitant increase in Bad phosphorylation in mouse brains [195]. Consistent with these 
effects, the ischemia-induced increase in Bad protein level and caspase-3 activation was suppressed in 
TGF-β1-transduced brain. Consequently, DNA fragmentation, ischemic lesions, and neurological 
deficiency were significantly reduced suggesting that TGF-β1 suppresses Bad expression under lesion 
conditions, increases Bad phosphorylation, and activates the MAPK/Erk pathway, which may 
contribute to its neuroprotective activity [195]. Nevertheless, the detrimental effects of homeostasis 
and the activation of multiple pathways with opposing signals following ischemic stroke indicate that 
better outcome probably does not depend on a single compound such as TGF-β1 but on several drugs 
acting in combination at the optimal time in a particular patient [196]. TGF-β pretreatment protected 
cultured hippocampal neurons from apoptotic degeneration caused by incubation with beta-amyloid 
peptide (Aβ). Aβ decreased mRNA expression of Bcl-2 expected to promote apoptosis. Incubation 
with TGF-β before the addition of Aβ reversed these changes even in the presence of Aβ [197]. 
Furthermore, the neurotoxic effect of Aβ was amplified by SB431542, a selective inhibitor of TGF-β 
receptor suggesting that TGF-β acts as a factor limiting Aβ toxicity. In pure cultures of rat cortical 
neurons TGF-β prevented Aβ-induced cell cycle reactivation, whereas lately added TGF-beta1 had no 
effect on the cell cycle, but rescued the late beta-catenin degradation and tau hyperphosphorylation. 
The phosphatidylinositol-3-kinase (PI-3-K) inhibitor, LY294402, abrogated all effects suggesting that 
TGF-β blocks the whole cascade of events leading to Aβ neurotoxicity by activating the PI-3-K 
pathway [198]. 
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As opposed to the effect of TGF-βs on the survival of neurons, they exert apoptotic effects on 
several other cell types. Growth factors can define the survival of neural stem cells whose vitality is 
critical for the growth of the developing brain. TGF-β1 exerted apoptotic activity on cultured stem 
cells [199], glioma cells [200], oligodendroglial progenitor cells [201], and Schwann cells [33]. 
Particularly relevant for neuroprotective disorders is the apoptotic activity of TGF-β1 on microglial 
cells participating in the immune response of the nervous system. In a study testing the effect of  
TGF-β1 on microglia, astrocytes and oligodendrocytes from newborn rats, TGF-β1 selectively induced 
apoptosis of microglia, and not of astrocytes or oligodendrocytes. A direct effect of TGF-β1 was 
implied as the expressions of other cytokines did not change [202]. Furthermore, the relative protein 
expression of bcl-2 in microglia was not related to frequency of microglial apoptosis suggesting that 
TGF-β1-induced microglial apoptosis was regulated by a bcl-2-independent mechanism [203]. 
Among TGF-βs, most experiments either did not discriminate between the subtypes or were specific 
for TGF-β1. In turn, the role of TGF-β2 and -β3 in mediating apoptosis in non-neuronal tissue was also 
established. Programmed cell death was significantly reduced in the intestinal mucosa of TGF-β2(+/−) 
and TGF-β3(+/−) heterozygous mice. This decrease in apoptosis was accompanied by an increase in 
villus length while proliferation remained unchanged. The level of Bcl-xL and Bcl-2 was significantly 
up-regulated in TGF-β2(+/−) and TGF-β3(+/−) mice suggesting that TGF-β2 and TGF-β3 play an 
important role in mediating apoptosis in the intestinal mucosa [204]. 
9.4. Protection against Excitotoxicity 
TGF-βs may also affect synaptic functions. Recently, it was demonstrated that TGF-β1 reduced 
synaptic transfer [35] suggesting that TGF-βs might be able to play a role in counteracting excitotoxic 
neuronal loss due to the excessive release of glutamate in the peri-infarct area. 
TGF-β1 added to cultured cerebral cortical neurons, increased the viability of the cultures 
determined using trypan blue exclusion. TGF-β1 also significantly reduced the excitotoxic neuronal 
damage in a concentration-dependent manner suggesting that TGF-β1 has the capacity to diminish the 
deleterious consequences of an excitotoxic insult [205]. TGF-β1 also protected against chronic 
glutamate toxicity in organotypic tissue cultures [206]. It was also possible to antagonize the protective 
effects exerted by TGF-β1 against excitotoxicity. A soluble receptor of TGF-β1 eliminated the 
neuroprotective activity of TGF-β1 in N-methyl-D-aspartate (NMDA)-induced excitotoxic cell death  
in vitro as well as in vivo [66]. Later, it has been suggested that PAI-1, an inhibitor of the serine 
protease tissue-type plasminogen activator might mediate the neuroprotective activity of TGF-β1 
against NMDA receptor-mediated excitotoxicity [207]. Some evidence is also available for a 
contribution of TGF-β1 in excitotoxic damage. Intraneocortical injection of ibotenate, a glutamate 
analog, in newborn mice produces damage mimicking lesions observed in human infants with cerebral 
palsy. Pretreatment with TGF-β1 exacerbated the ibotenate-induced lesion while a TGF-β1 
neutralizing antibody diminished it [208]. 
TGF-β subtypes other than TGF-β1 were also implicated in excitotoxicity. TGF-β1 and -β3 but not 
TGF-β2 were able to prevent the degeneration of cultured chick embryo telencephalic neurons that had 
been exposed to 1 mM L-glutamate for a period of 60 min [209]. In addition, neuronal death induced 
by brief NMDA exposure in both mixed neuronal-glial and pure neuronal cultures was increased by 
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TGF-β2 with a similar dose-response curve. These findings indicate that TGF-β2 may potentiate 
excitotoxicity [210]. 
Information on the mechanism how TGF-βs affect excitotoxicity is scarce. TGF-β1 augmented the 
expression of some key subunits of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic  
acid (AMPA) and NMDA receptors in the hippocampus. Treatment of cultured hippocampal neurons 
with TGF-β1 enhanced glutamate-evoked currents [211]. 
9.5. Angiogenesis 
TGF-β was shown to promote angiogenesis. When injected subcutaneously in newborn mice,  
TGF-β induced angiogenesis and activated fibroblasts to produce collagen at the site of injection.  
In addition, in vitro studies showed that TGF-β caused marked increase of proline and leucine 
incorporation into collagen in rat and human fibroblasts cell lines [212]. A direct effect of TGF-β on 
angiogenesis was later questioned. It has been suggested that TGF-β1 can potentiate the effect of other 
growth factors. Indeed, TGF-β1 increased the effect of vascular endothelial growth factor  
(VEGF)-induced angiogenesis in a model, in which microvascular endothelial cells formed  
capillary-like tubes within collagen gels [213]. Using a similar three-dimensional hydrated collagen gel 
as well as two-dimensional Petri dish cultures, low concentrations of TGF-β1 enhanced the stimulatory 
effects of basic fibroblast growth factor [214]. In vivo, in disc angiogenesis system, TGF-β1 also 
potentiated the proliferation of endothelial cells. To test the role of endogenous TGF-β in the 
spontaneous angiogenesis of wound healing, a monoclonal anti-TGF-β antibody was applied, which 
decreased the spontaneous vascular growth below the level of controls [215]. Thus, endogenous  
TGF-β has the potential to contribute to spontaneous angiogenesis, e.g., during wound healing.  
In addition, knockout mice for the different components of the TGF-β signaling pathway have shown 
that TGF-β is indispensable for angiogenesis and mutations in TGF-β receptors have been linked to a 
vascular disorder named hereditary hemorrhagic telangiectasia [216]. In the brain, similar mechanisms 
are expected for angiogenesis although the available data is less abundant. A complex interplay 
between TGF-β1 and vascular endothelial growth factor has been suggested. Both of them induced 
angiogenesis but had opposing effects on endothelial cells. VEGF protected endothelial cells from 
apoptosis while TGF-β1 induced apoptosis. Furthermore, the inhibition of VEGF blocked both 
apoptosis and angiogenesis elicited by TGF-β1 suggesting refined control of angiogenesis by the 
interplay of these growth factors [217]. 
Angiogenesis is also an important part of tumor growth in vivo. The overproduction of TGF-β1 by 
tumor cells can contribute to neovascularization and may help promote tumor development  
in vivo [218]. TGF-βs are particularly involved in malignant gliomas characterized by excessive 
proliferation, infiltrative growth, angiogenesis and suppression of anti-tumor immune surveillance. The 
effects of TGF-β in glioma biology include a survival advantage for glioma cells by enforced cell 
growth, migration, invasion, angiogenesis and immune paralysis [158]. 
9.6. Neuronal Regeneration 
Establishing a direct role of TGF-β in neuronal regeneration requires an examination of the 
potential involvement of scar formation because an indirect effect by fibrosis and astrogliosis is always 
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a possibility. For example, continuous infusion of a small molecule inhibitor of type I TGF-β receptor 
kinase LY-364947 resulted in the regeneration of tyrosine hydroxylase-immunoreactive after a 
unilateral transection of the nigrostriatal dopaminergic pathway [181]. In the injured brain, infusion of 
LY-364947 suppressed fibrotic scar formation and decreased the numbers of reactive astrocytes in the 
lesion site indicating that TGF-β signaling contributes to the fibrotic scar and the blockade of axonal 
regeneration [181]. Some evidence also exists on the direct role of TGF-β in neuronal regeneration. 
When axons of cultured rat hippocampal neurons cut by local irradiation of laser beam, the axonal 
growth was stopped by laser irradiation. Addition of TGF-β remarkably promoted the axonal  
re-elongation from the injured site in a concentration dependent manner suggesting that TGF-β1 has a 
capability of promoting axonal regeneration of brain neurons after lesioning [211,219]. Some of these 
effects may be mediated by other growth factors. Nerve growth factor (NGF), which is known to 
influence neuronal development, function, and response to injury, is regulated by at least two 
promoters that govern synthesis of four different transcripts, A through D. TGF-β1 induced NGF 
mRNA and protein in rat and mouse glia but not in neurons. Furthermore, transcripts A, B and D, but 
not C, are upregulated by TGF-beta1 in mouse glia, whereas in rat glia, the major responsive transcript 
is C [220]. Altogether, these results provide some evidence that NGF might mediate the effects of 
TGF-β1 on neuroregeneration. 
Apart from affecting axonal outgrowth, TGF-βs may also participate in other aspect of neuronal 
regeneration such as synaptogenesis and the regeneration of dendritic spines. It has been demonstrated 
that TGF-β1 facilitated synaptogenesis in Xenopus nerve-muscle co-cultures [34] and it may also 
contribute to changing dendritic morphology following brain injury [221]. 
10. Conclusions  
The described mechanisms of actions of TGF-β are not equally well established. The  
anti-inflammatory action of TGF-βs is fully proved. A substantial amount of evidence is available to 
support the role of TGF-βs in scar formation including astrogliosis. TGF-β is known to affect cell 
survival, and an anti-apoptotic effect on neurons is supported by a number of experiments. A role of 
TGF-βs in excitotoxicity has also been intensively investigated. Similarly, the available evidence is 
strong for a role of TGF-βs to angiogenesis and their contribution to the vascularization of tumors. 
Finally, neuronal regeneration might also involve TGF-βs.  
The contribution of these mechanisms varies depending on the type of brain lesion (Figure 1). The 
role of neuroinflammation has been recognized in a diverse range of cerebral pathologies, including 
ischemic and traumatic brain injury. Sclerosis multiplex is an inflammatory disease, in which an  
anti-inflammatory protein can play obvious roles. Neurodegenerative disorders might also include an 
inflammatory aspect. In turn, pathogens often develop ways to protect against inflammatory host 
defense mechanisms. Therefore, TGF-β may not be very effective against infections.  
Apoptosis is prominent for cerebral ischemia and traumatic brain injury around the area of the 
primary damage. This is a clinically relevant region because of the realistic chance for preserving this 
tissue by treatment. Anti-apoptotic and anti-excitotoxic effects of TGF-β could be relevant when 
aiming at developing neuroprotective agents (Figure 2). Furthermore, the occlusion of cerebral vessels 
during stroke is followed by proliferation of microvessels, i.e., angiogenesis. This process is also 
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particularly marked in the border zone of the infarct, the ischemic penumbra, where a decreased blood 
flow is following focal ischemia. This increase in vascularization is another process, in which TGF-β 
could play a role following brain injuries as increasing blood flow in this vulnerable region can 
alleviate the consequences of an ischemic attack. The involvement of TGF-β in neuroregeneration is 
not fully proved while its effect in scar formation remains controversial as to its contribution of 
neuroprotection following any brain lesion. Therefore, the potential contribution of these mechanisms 
to the neuroprotective actions of TGF-β is low. 
Figure 2. The contribution of TGF-β effects to its neuroprotective actions in different brain 
lesions. In the left mechanisms are listed, through which TGF-β effects are exerted on 
neuronal tissue. The size of the arrow indicates the general importance of the particular 
mechanism in conveying the neuroprotective actions of TGF-β. A white arrow belongs to 
scar formation because this action of TGF-β may not necessarily be neuroprotective.  
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